

Reduce the Risk: PCI Bleed

A Campaign of the American College of Cardiology



ACC REDUCE THE RISK: PCI BLEED

Webinar # 5
USING THE PCI BLEEDING RISK CAMPAIGN TO
AFFECT PATIENT OUTCOMES

August 23, 2018 12:00-1:00pm EST



Hosted by;

Andrea Price MS, CPHQ, RCIS, AACC
Director- Quality Databases, Indiana University Health
Reduce the Risk PCI Bleed Steering Committee Chair

Sunil Rao MD, FACC
Reduce the Risk PCI Bleed Steering Committee Member



Agenda

- 1. ACC Quality Campaign Framework and Design and History
- 2. Reduce the Risk: PCI Bleed Campaign Goals
- 3. Campaign Metrics
- 4. The Change Package/the Campaign Features
- 5. Getting Started




Quality Campaign Goals...

- Help hospitals improve cardiovascular care.
- To improve the quality and value of cardiovascular care and outcomes.

Leverage evidence-based practices.



What's in an ACC Quality Campaign? 4 Parts



*Key characteristics of a successful QI program

- Influential
- Credible
- Simple
- Strategically aligned for participant
- Offers practical implementation tools
- Offers Networking
- Sets Attainable goals



*Bradley, E. H., Nembhard, I. M., Yuan, C. T., Stern, A. F., Curtis, J. P., Nallamothu, B. K., & ... Krumholz, H. M. (2010). What Is the Experience of National Quality Campaigns? Views from the Field What Is the Experience of National Quality Campaigns?. Health Services Research, 45(6p1), 1651-1669.

Potential Quality Campaign Feasibility Framework

Need to Strategic Internal/ Measureable implementation improve alignment external levers Outcomes strategies Champions Funding





Reduce the Risk: PCI Bleed-Feasibility Assessment

A. Primary Purpose

bleeding adverse events

B. Aligned with ACC strategic plan and mission

C. Evidence of need to improve

2.65% to 9.36%

 70% of hospital variability due to unexplained causes

<u>Guidelines</u>

- Evaluate bleeding risk (1C PCI)
- ACS treated with DAPT after stent and not high risk of bleeding and no hx of stroke/TIA use prasagrel over clopidogrel (IIA DAPT)

NCDR dashboard

- ½ CathPCI sites have median RAB = 4.16% or higher.
- 90th percentile of hospitals have RAB 1.6% or lower.

D. Drivers

- BCBSA
- MACRA CPI
- NQF
- MOC

E. Draft QI aim statement(s)

widespread adoption of evidencebased practices to improve quality of care.

F. Outcome measures

pts

- #1289) Post proc bleeding
- (#1602) Bivalirudin w/I 24hrs of all PCI pts
- (#1827) Unadjusted bleeding events
- (#1871) Post proc bleeding for STEMI pts

ACTION

(#42) In-hospital RAB

G. Evidence based implementation metrics

H. Internal levers

- CathPCI
- •ACTION
- •<u>Guideline</u> references

PCI

DAPT

Accreditation

•CathLab related standards

<u>Tools</u>

- PCI bleeding toolkit
 ACC Quality programs
- PMAC pathway

I. Funding

ACC/NCDR at the moment.

Pharma:

- •AZ-Brillinta
- Daiichi Sankyo/Eli Lilly Prasugrel
- •TMC Bivalirudin

Transradial:

• St. Jude, Medtronic, BSC

K. Overall program design

champions and

J. Program

experts

- Assessment survey
- Intervention tools
- Education
- Feedback

<u>Learning Network</u>

- Listserv
- QII website
- Conferences
- Chapter meetings
- Receptions

Recognition

- Quality Leader Hospitals
- •General recognition

Evaluation Plan

- Program reach
- Clinical care
- Adoption

Agenda

- ACC Quality Campaign Framework and Design and History
- 2. Reduce the Risk: PCI Bleed Campaign Goals
- 3. Campaign Metrics
- 4. The Change Package /the Campaign Features
- 5. Getting Started



Reduce the Risk: PCI Bleed Quality Campaign

motivating
widespread adoption
of evidence-based
practices to improve
quality of care

Improve bleeding rates and decrease variances in data


Decreasing Bleeding Rates



- All patients should be evaluated for risk of bleeding before PCI.
- Patients considered high risk for PCI should be part of a collaborative decision to use a **radial** approach.
- In patients with ACS treated with DAPT after coronary stent implantation who are not at high risk for bleeding complications and who do not have a history of stroke or TIA, it is reasonable to choose Prasugrel over Clopidogrel for maintenance P2Y12 inhibitor therapy.
- In patients with SIHD treated with DAI Tafter DES implantation who are at high risk of severe bleeding complication or develop significant of Part (meding, discosting tion of Part 2) inhibitor therapy after 3 months may be reasonable.
- In patients with SIHD treated with DAPT after BMS or DES implantion who have tolerated DAPT without a bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), continuation of DAPT with clopidogrel for longer than 1 month in patients treated with BMS or longer than 6 months in patients treated with DES may be reasonable.



Opportunity for Improvement





Steering Committee Members

Andrea Price, MS, RCIS, CCA Indiana University

Committee Chair

Amit Amin, MD, FACC Barnes Jewish Hospital

John Messenger, MD, FACC University of Colorado Hospital

Julie Miller, MD, FACC Johns Hopkins Hospital

Issam Moussa, MD, FACC Robert Wood Johnson University Hospital

Sunil V. Rao, MD, FACC Duke University Medical Center

Agenda

- 1. ACC Quality Campaign Framework and Design and History
- 2. Reduce the Risk: PCI Bleed Campaign Goals
- 3. Campaign Metrics
- 4. The Change Package/the Campaign Features
- 5. Getting Started



#	Program Metric	Metric Description							
1	PCI in-hospital risk-standardized rate of bleeding events for all PCI patients	Bleeding complications after PCI are associated with increased morbidity, mortality and costs. This measure is helpful in providing risk-adjusted feedback on bleeding complications, informing clinical decision-making, and directing the use of bleeding avoidance strategies to improve the safety of PCI procedures.							
2	Proportion of PCI procedures with transfusion of whole blood or red blood cells	Numerator: Count of PCI procedures with <u>a</u> RBC/Whole blood transfusion procedure. Denominator: Count of PCI Procedures The purpose of this metric is to allow identification of potential overuse of transfusion after PCI procedures. In addition, it points out blood loss, which predicts poor outcomes.							
3	Procedures with an observed bleeding event	Count of bleeding event post PCI procedure.							
4	Anticoagulation utilization	All Anticoagulants Fondaparinux Low molecular weight heparin (any) Unfractionated heparin (any) Heparin-LMWH/Unfractionated(any) Direct thrombin inhibitors Bivalirudin							
5	Access site utilization. Indicate the primary location of percutaneous entry. Code the site used to perform most of the procedure if more than one site was used.	Femoral Brachial Radial Other							
6	Method for closure for arterial access site. Indicate the arterial closure methods used in chronological order regardless of whether they provided hemostasis. The same closure method may be repeated	Manual compression Mechanical compression Suture Staple Sealant Patch Other, unspecified device							



A new, hierarchical risk-standardized model



PCI in-hospital
risk standardized
rate of bleeding events
(all patients)



Performance Measure #40: What's new

- Hierarchical model
- Fewer patient variables
- Risk relationships within and amongst hospitals
- Absolute Hgb decrease from pre-PCI to post-PCI of 4g/dL (previously 3g/dL)



Performance Measure #40: Model Details

Post-PCI bleeding defined as any ONE of the following:

- 1. Bleeding event w/in 72 hours OR
- 2. Hemorrhagic stroke OR
- 3. Tamponade OR
- 4. Post-PCI transfusion for patients with a pre-procedure Hgb >8 g/dL and pre-procedure Hgb not missing; OR
- 5. Absolute Hgb decrease from pre-PCl to post-PCl of ≥ 4 g/dL

Performance Measure #40: Model Details Patient eligibility:

- 1. Patient's with a PCI procedure performed during the Episode of Care.
- 2. Patients with multiple PCI procedures Include only index PCI procedure.
- 3. Include patient procedures with non-missing values for outcome variables of bleeding event w/in 72 hours AND transfusion.
- 4. Exclude patients who died on the same day of the procedure.
- 5. Exclude patients with CABG.



Agenda

- 1. ACC Quality Campaign Framework and Design and History
- 2. Reduce the Risk: PCI Bleed Campaign Goals
- 3. Campaign Metrics
- 4. The Change Package/ the Campaign Features
- 5. Getting Started





QII Participant Change Package



listsery who share best practices and

lessons learned. Read More...



(8 possible points)

Campaign Assessment Tool





A Campaign of the American College of Cardiology

- ▶ About Reduce the Risk
- ▶ Getting Started
- Reduce the Risk Features

Assessment

Toolkit

Webinars

Reduce the Risk Listserv

Reduce the Risk - PCI Bleed Participation

Certificate



Reduce the Risk: PCI Bleed Toolkit

The ACC has curated evidence-based tools to help you decrease PCI bleeding at your facility. Click on each section to find targeted tools for each Campaign metric:

Metric 1: in-hospital risk-standardized rate of bleeding events for all PCI patients.

Metric 2: Proportion of PCI procedures with transfusion of whole blood or red blood cells.

Metric 3: Procedures with an observed bleeding event.

Metric 4: Anticoagulation utilization.

Metric 5: Access site utilization.

Metric 6: Method for closure for arterial access site.

- Preprocedural (Tools to address Metric #1 and 6)
- > Intraprocedural (Tools to address Metric #1, 5, and 6)
- Postprocedural (Tools to address Metric #1, 5, and 6)
- Pharmacotherapy (Tools to address Metric # 1, 2, 3, 4, 5, 6)

EHR Integration (Tools to address Metric #1, 4, 5, and 6)




Reduce the Risk: PCI Bleed Toolkit

✔ Preprocedural (Tools to address Metric #1 and 6)

Metric	Tools
Metric 1: in-hospital risk-standardized rate of bleeding Metric 3: Procedures with an observed bleeding event	CathPCI Bleeding Risk Calculator App
Metric 1: in-hospital risk-standardized rate of bleeding events for all PCI patients Metric 6: Method for closure for arterial access site	Pre PCI-Procedure Orders
Metric 1: in-hospital risk-standardized rate of bleeding Metric 3: Procedures with an observed bleeding event	The Universal Protocol from the Joint Commission
Metric 1: in-hospital risk-standardized rate of bleeding events for all PCI patients Metric 4: Anticoagulation utilization Metric 5: Access site utilization	Risk-Concordant Framework for Bleed Avoidance Strategies



Toolkit Aligned to Metrics





Early Warning Signs of a Vascular Complication After PCL

Multiple factors can lead to a bleed after a PCI. provides the most common vascular site complic

Complication	Definition
Hematoma Incidence: 5-23%	The localized blood-filled soft tissue swelling is the most common vascular access site complication.
	It may happen if puncture is b the femoral bifurcation.
P	Occurs with blood loss at arter and/or venous access site or arterial/venous perforation
Retroperitoneal Hemorrhage	membrane lining (the
Incidence: 0.15-0.44%	retroperitoneum) the abdomin wall and pelvis that may result from puncture below inguinal ligament leading to supraingual arterial or posterior wall perforation
Pseudoaneurysm	A disruption and dilation of the
Incidence: 0.5% - 9%	arterial wall creating a communicating tract between tissue layers. Often occurring between one of the weaker femoral artery walls leading to blood flowing into the tissue
	May result from arterial cannulation dysfunction, inadequate compression after sheath removal, impaired hemostasis and femoral punctubelow the bifurcation
teriovenous Fistula	A direct connection between ar

This tool is a part of the Bleeding Risk Toolkit available thr





Inappropriate sheath removal after a PCI can lead to adverse events for the patient, including vascular complications and additional surgical procedures. The following protocol can be used in a hospital setting to

Adapted with permission from the Blue Cross Blue Shield of Michigan Cardiovascular Collaborative (BMC2) Best practice protocols available

A dedicated sheath pulling team that has met competency requirements may be the best organizational

- 1. Confirm with recovery RN that:
- a. Patient is ready for sheath pull.
- b. Atropine available for vaso vagal response.
- c. Pertinent history: special considerations (i.e. previous groin complications).

Catheter/Sheath Type Femoral gortex graft access site.	Special Instructions
New iliac stept (same sides)	Manual hold only, no clamp.
New iliac stent (same side approach) or less than 6 months old.	Manual hold only, no clamp.
New iliac stent (opposite side approach)	was stamp.
old filde Stent (more than 6 man at 1	None
Antegrade approach	Manual hold only, no clamp.
Cardiac biopsy sheath	Manual hold only, no clamp
Brachial sheath	Must be removed in lab
Radial sheath	Monitor with pulse oximator
	Use of Hemo-band, Hemo hand
Aarkedly obese	
ortic insufficiency	
,	Will require longer hold time. If
BP > 180 mm Hg	hold, consider Compression Assist Device. Must be treated prior to removal.

2. Assess the patient for sheath pull.

- a. BP greater than 160 systolic and greater than 100 diastolic, contact attending or fellow.
- b. BP less than 90 systolic and heart rate less than 45 bpm (contact attending or fellow if BP is high or low). c. ACT less than 180 seconds when measured on the Hemochron Junior Signature.
- e. Visualize and assess the shooth inner the



Webinar #1: September 18, 2018 Webinar #2: November 7, 2018

Webinar #3: January 23, 2019 Webinar #4: May 22, 2019


Webinar #5: August 23, 2019 Webinar #6: November 6, 2019







The Campaign Dashboard







Dashboard Example

Facility Name and PID # CathPCI Quality Campaigns > Reduce the Risk PCI Bleed Campaign																					
		gne > Reduce the Rick DCI Blood Campaign		2017Q2		2017Q3			2017Q4			2018Q1			My Hospital R4Q		R4Q	US Vol Group Pts R4Q		US Registry Pts R4Q	
catherity	uanty Campai	gns e neutre the trisk ect bleed campaign		G			G			G			G								
			Num	Den	%	Num	Den	%	Num	Den	%	Num	Den	%	Num	Den	%	Num	%	Num	%
	Metric Key	Description																			
Metric 1	4934	PCI In hospital risk- standardized rate of bleeding events	1,000			435			406			416			2,257			315,333		1,467,135	
Metric 2	4288	Proportion of PCI proceedures with transfusion of whole or RBC	934	1,000	93.4	383	435	88.1	345	406	85.0	341	416	82.0	2,003	2,257	88.8	295,309	93.7	1,410,930	96.2
Metric 3	4928	Proceedures with an observed bleeding rate	445	1,000	44.5	435	435	100.0	406	406	100.0	416	416	100.0	1,702	2,257	75.4	184,405	58.5	735,584	50.
Metric 4		Anticoagulation Utilization	1,000	1,000	100.0	43	435	9.9	44	406	10.8	23	416	5.5	251	2,257	11.1	66,285	21.0	313,113	21.3
	4466	All anticoagulants	374	1,000	37.4	381	435	87.6	342	406	84.2	341	416	82.0	1,438	2,257	63.7	160,615	50.9	666,023	45.4
	4467	Fondaparinux	5	1,000	0.5	2	435	0.5	3	406	0.7	0	416	0.0	10	2,257	0.4	3,766	1.2		0.9
	4468	Low molecular weight heparin	451	1,000	0.5	446	435	102.5	414	406	102.0	426	416	102.4	1,737	1,702	102.1	190,288	103.2	758,264	103.
	4469	Unfractionated heparin	50		0.1																
	8944	Heparin-LMWH/Unfractionated	50	1,000	0.1																
	4471	Bivalirudin	374	1,000	37.4	381	435	87.6	342	406	84.2	341	416	82.0	1,438	2,257	63.7	160,615	50.9	666,023	45.4
Metric 5		Access site utilization																			
	4159	Femoral access site	1,000	1,000	100.0	43	435	9.9	44	406	10.8	23	416	5.5	251	2,257	11.1	66,285	21.0	313,113	21.
	4161	Brachial access site	374	1,000	37.4	381	435	87.6	342	406	84.2	341	416	82.0	1,438	2,257	63.7	160,615	50.9	666,023	45.
	4163	Radial access site		1,000	0.5	2	435	0.5	3	406	0.7	0	416	0.0	10	2,257	0.4	3,766	1.2	13,418	0.
	4165	Other access site	45	1,000	0.5	446	435	102.5	414	406	102.0	426	416	102.4	1,737	1,702	102.1	190,288	103.2	758,264	103
Metric 6		Method for closure for arterial access site																			
	4167	Manual compression	934	1,000	93.4	383	435	88.1	345	406	85.0	341	416	82.0	2,003	2,257	88.8	295,309	93.7	1,410,930	96.2
	4169	Mechanical compression	445	1,000	44.5	435	435	100.0	406	406	100.0	416	416	100.0	1,702	2,257	75.4	184,405	58.5	735,584	50.1
	4171	Suture closure method	1,000	1,000	100.0	43	435	9.9	44	406	10.8	23	416	5.5	251	2,257	11.1	66,285	21.0	313,113	21.3
	4173	Staple closure method	374	1,000	37.4	381	435	87.6	342	406	84.2	341	416	82.0	1,438	2,257	63.7	160,615	50.9	666,023	45.4
	4175	Sealant closure method	5	1,000	0.5	2	435	0.5	3	406	0.7	0	416	0.0	10	2,257	0.4	3,766	1.2	13,418	0.9
	4177	Patch closure method	451	1,000	0.5	446	435	102.5	414	406	102.0	426	416	102.4	1,737	1,702	102.1	190,288	103.2	758,264	103.1
				-	$\overline{}$	_		_			_	_							-		





Agenda

- 1. ACC Quality Campaign Framework and Design and History
- 2. Reduce the Risk: PCI Bleed Campaign Goals
- 3. Campaign Metrics
- 4. The Change Package/ the Campaign Features
- 5. Getting Started



Opt in today!

To become a Reduce the Risk: PCI Bleed facility"

- 1. Log into NCDR
- 2. Go to your CathPCI Registry® home page
- 3. Click "Start Here" on the left navigation bar
- 4. Opt in!

The Registry Site Manager will be required to log in to opt your facility into the program.



Reduce the Risk: PCI Bleed

Anticipate. Prepare. Save Lives.

The ACC's Reduce the Risk: PCI Bleed Quality Campaign is focused on minimizing PCI-associated bleeding risks and saving patient lives through widespread adoption of evidence-based best practices.

Building on the ACC's proven track record in helping hospitals and cardiovascular professionals take advantage of key strategies to close gaps in guideline-recommended care, **Reduce the Risk: PCI Bleed** leverages the power of the CathPCI Registry[®] to help hospitals and clinicians anticipate, prepare and save lives.



A Campaign of the American College of Cardiology

Join the Reduce the Risk: PCI Bleed Campaign

Join **Reduce the Risk: PCI Bleed** and be recognized for your commitment to Quality! Participation is easy and no additional cost to CathPCI Registry participants!



Opting in Link



CathPCI Registry®

Switch Registry V

Veronica Wilson | American College of Cardiology | Logout

CathPCI Registry / Home / Announcements

Home

START HERE

Dashboard

Corporate Dashboard

Chapters Dashboard

- ▶ Data
- Resources
- ▶ Control

Public Links

Quality Improvement for Institutions Home

NCDR Home

Welcome CathPCI Registry Participants

Locate the v5 Pending Data Dictionary Updates

As dynamic, real-world scenarios are captured in the v5 dataset areas for improvement are rapidly being identified! Please locate the document: v5 Dynamic Lists and Definitions with Pending Data Dictionary Updates on the resource page. This document will support accurate data capture and be updated as needed until the Data Dictionary can be amended. Thank you for checking the announcement page frequently!

Posted Jun 11, 2018

NCDR.18 Annual Conference: Sessions on Demand (recordings)

Thank you again for attending the NCDR.18 Annual Conference in Orlando, Florida earlier this year.

For those of you who purchased the NCDR.18 Sessions on Demand (recordings) already, we received some feedback that the session titles did not completely mirror the ones used onsite. We appreciate your feedback and are happy to inform you that all session itiles have now been updated. If you have not yet received your login credentials to access the recordings, please contact us at nodr@acc.org or 800-257-4737.

If you have not purchased the NCDR.18 Sessions on Demand and wish to do so now, please use the following link: http://www.conferencemedia.net/stores/ncdr/

We look forward to seeing you at NCDR.19 in New Orleans!

Posted Jun 11, 2018

NCDR Orientation 101 Webinar Occurs Tuesday June 12th 2018

Please join us on June 12th 2018, from 1pm – 3pm Eastern Time as we walk you through getting started with NCDR. We'll arm you with information about website navigation, business processes, available resources and much more!

Participants will be muted in this session, and are welcome to ask questions via the Q-and-A functionality displayed on the screen during the session. The NCDR Clinical Quality Advisor Team will lead this session, and will answer as many questions as possible!

Click Here to Join the April 10th 2018 Webinar!







Opt In

Reduce the Risk: PCI Bleed Campaign Opt in Opt out page

OPT IN

Attention Registry Site Managers: To opt into the Patient Navigator Program Focus MI, please acknowledge your understanding of the program requirements by clicking the box below and submitting:



Click here to accept the terms and conditions of the Patient Navigator Program Focus MI

Submit

QUESTIONS?





Reduce the Risk: PCI Bleed

A Campaign of the American College of Cardiology